Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I
Executive Summary
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.
You may also be interested in...
Frontrunner Kymera Claims Proof-Of-Concept For Protein Degrader Platform
Kymera has unveiled the first placebo-controlled data from a protein degradation candidate, adding to heightened expectations for the novel modality.
Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader
Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.
New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
In 2020, investors poured millions of dollars into biotech companies searching for new therapeutics that interact with cellular processes involving the destruction and recycling of cellular proteins. These protein degradation-targeted therapies, and molecular glues, have been attracting the attention of big pharma too.